Microbubble contrast agent SonoVue combined with oxytocin improves the efficiency of high-intensity focused ultrasound ablation for adenomyosis.

Yao R, Zhao W, Gao B, Hu J, Wang T

International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group1 Jan 2021Cited by 8 (Europe PMC)

PMID34763594DOI10.1080/02656736.2021.1993357PepBankPUB-34763594

Download PDF PubMedAsk about this study

Jump to 7 results

Summary

BackgroundTo investigate the combined enhancing effects of microbubble-contrast SonoVue and oxytocin on high-intensity focused ultrasound (HIFU) ablation of adenomyosis.Methods330 patients with adenomyosis were randomly assigned to SonoVue and oxytocin group (group A, n = 82), oxytocin (group B, n = 85), SonoVue (group C, n = 81), or the control (group D, n = 82) for HIFU ablation. In group A, oxytocin was dripped 0.32 IU/min, and HIFU ablation was started one minute after SonoVue injection. In group B, oxytocin was dripped 0.32 IU/min during ablation. In group C, HIFU ablation was started one minute after SonoVue injection. In group D, neither oxytocin nor SonoVue was applied. The clinical data, treatment results, and complications were analyzed.ResultsAll participants underwent HIFU treatment safely, and the mean energy efficiency factor (EEF) in the four groups was 4.7 ± 0.9J/mm³, 8.5 ± 0.6J/mm³, 8.9 ± 0.7J/mm³, and 12.6 ± 1.8J/mm³, respectively, with the mean ablation time (AT) of 633.7 ± 55.1 s, 874.2 ± 65.6 s, 936.3 ± 85.2 s, and 1103.2 ± 96.2 s, respectively. The non-perfused volume ratios (NPVR) were 90.4 ± 8.8%, 88.7 ± 9.1%, 89.4 ± 7.2%, 80.5 ± 7.9%, respectively. In addition, EEF and AT were the shortest in group A (p < 0.05). NPVR was significantly higher in group A than in the control group D (p < 0.05). The incidence rates of adverse events were not significantly different in the four groups (p > 0.05).ConclusionsCompared to the control group, oxytocin combined with SonoVue in HIFU for adenomyosis can significantly decrease the energy and time needed for the ablation and safely enhance the treatment efficiency by improving the cavitation and heating of HIFU ablation and increasing the non-perfused volume ratio.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with adenomyosis having HIFU ablation, the mean energy efficiency factor was lower with oxytocin alone than in controls (no test reported for this pair).
In plain wordsIn women having ultrasound ablation for adenomyosis, oxytocin alone was linked to lower energy need than none; no test is given.
Peptide
Oxytocin
Outcome
DecreaseEnergy efficiency factor with oxytocin alone
Study
n = 167
Comparator
Control (neither oxytocin nor SonoVue)
Outcome group
Uterine fibroid outcomes · Reproductive and sexual health
Studied dose
0.32 IU/min · during ablationAs given in this study (human).
Measurements
EEF
8.5 J/mm3
oxytocin alone (group B)
EEF
12.6 J/mm3
control (group D)
Source sentences
Summary
All participants underwent HIFU treatment safely, and the mean energy efficiency factor (EEF) in the four groups was 4.7 ± 0.9J/mm³, 8.5 ± 0.6J/mm³, 8.9 ± 0.7J/mm³, and 12.6 ± 1.8J/mm³, respectively, with the mean ablation time (AT) of 633.7 ± 55.1 s, 874.2 ± 65.6 s, 936.3 ± 85.2 s, and 1103.2 ± 96.2 s, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
330 patients with adenomyosis were randomly assigned to SonoVue and oxytocin group (group A, n = 82), oxytocin (group B, n = 85), SonoVue (group C, n = 81), or the control (group D, n = 82) for HIFU ablation.
Summary · context
In group B, oxytocin was dripped 0.32 IU/min during ablation.
Show in the study text Report a problemFND-3476359401
02HumanRandomized controlled trialEfficacy outcome
In women with adenomyosis having HIFU ablation, the mean ablation time was shorter with oxytocin alone than in controls (no test reported for this pair).
In plain wordsIn women having ultrasound ablation for adenomyosis, oxytocin alone was linked to shorter ablation time than none; no test is given.
Peptide
Oxytocin
Outcome
DecreaseAblation time with oxytocin alone
Study
n = 167
Comparator
Control (neither oxytocin nor SonoVue)
Outcome group
Uterine fibroid outcomes · Reproductive and sexual health
Studied dose
0.32 IU/min · during ablationAs given in this study (human).
Measurements
AT
874.2 s
oxytocin alone (group B)
AT
1103.2 s
control (group D)
Source sentences
Summary
All participants underwent HIFU treatment safely, and the mean energy efficiency factor (EEF) in the four groups was 4.7 ± 0.9J/mm³, 8.5 ± 0.6J/mm³, 8.9 ± 0.7J/mm³, and 12.6 ± 1.8J/mm³, respectively, with the mean ablation time (AT) of 633.7 ± 55.1 s, 874.2 ± 65.6 s, 936.3 ± 85.2 s, and 1103.2 ± 96.2 s, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
330 patients with adenomyosis were randomly assigned to SonoVue and oxytocin group (group A, n = 82), oxytocin (group B, n = 85), SonoVue (group C, n = 81), or the control (group D, n = 82) for HIFU ablation.
Summary · context
In group B, oxytocin was dripped 0.32 IU/min during ablation.
Show in the study text Report a problemFND-3476359402
03HumanRandomized controlled trialEfficacy outcome
In women with adenomyosis having HIFU ablation, the non-perfused volume ratio was higher with oxytocin alone than in controls (no test reported for this pair).
In plain wordsIn women having ultrasound ablation for adenomyosis, oxytocin alone was linked to a higher non-perfused volume ratio than none; no test is given.
Peptide
Oxytocin
Outcome
IncreaseNon-perfused volume ratio with oxytocin alone
Study
n = 167
Comparator
Control (neither oxytocin nor SonoVue)
Outcome group
Uterine fibroid outcomes · Reproductive and sexual health
Studied dose
0.32 IU/min · during ablationAs given in this study (human).
Measurements
NPVR
88.7%
oxytocin alone (group B)
NPVR
80.5%
control (group D)
Source sentences
Summary
The non-perfused volume ratios (NPVR) were 90.4 ± 8.8%, 88.7 ± 9.1%, 89.4 ± 7.2%, 80.5 ± 7.9%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
330 patients with adenomyosis were randomly assigned to SonoVue and oxytocin group (group A, n = 82), oxytocin (group B, n = 85), SonoVue (group C, n = 81), or the control (group D, n = 82) for HIFU ablation.
Summary · context
In group B, oxytocin was dripped 0.32 IU/min during ablation.
Show in the study text Report a problemFND-3476359403

Studies that did not test the peptide alone4

In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Oxytocin.

04HumanNot a test of Oxytocin aloneRandomized controlled trialEfficacy outcome
In women with adenomyosis having HIFU ablation, the combination of SonoVue and oxytocin gave the shortest energy efficiency factor among the four groups.
In plain wordsIn women with adenomyosis having ultrasound ablation, SonoVue plus oxytocin needed the least energy of the four groups.
Peptide
Oxytocin
Outcome
DecreaseEnergy efficiency factor with SonoVue plus oxytocin
Study
n = 330
Comparator
Three other groups
Outcome group
Uterine fibroid outcomes · Reproductive and sexual health
Measurements
EEF
4.7 J/mm3
SonoVue plus oxytocin (group A)
Source sentences
Summary
In addition, EEF and AT were the shortest in group A (p < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
All participants underwent HIFU treatment safely, and the mean energy efficiency factor (EEF) in the four groups was 4.7 ± 0.9J/mm³, 8.5 ± 0.6J/mm³, 8.9 ± 0.7J/mm³, and 12.6 ± 1.8J/mm³, respectively, with the mean ablation time (AT) of 633.7 ± 55.1 s, 874.2 ± 65.6 s, 936.3 ± 85.2 s, and 1103.2 ± 96.2 s, respectively.
Summary · context
330 patients with adenomyosis were randomly assigned to SonoVue and oxytocin group (group A, n = 82), oxytocin (group B, n = 85), SonoVue (group C, n = 81), or the control (group D, n = 82) for HIFU ablation.
Summary · context
In group B, oxytocin was dripped 0.32 IU/min during ablation.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Show in the study text Report a problemFND-3476359404
05HumanNot a test of Oxytocin aloneRandomized controlled trialEfficacy outcome
In women with adenomyosis having HIFU ablation, the combination of SonoVue and oxytocin gave the shortest ablation time among the four groups.
In plain wordsIn women with adenomyosis having ultrasound ablation, SonoVue plus oxytocin gave the shortest ablation time of the four groups.
Peptide
Oxytocin
Outcome
DecreaseAblation time with SonoVue plus oxytocin
Study
n = 330
Comparator
Three other groups
Outcome group
Uterine fibroid outcomes · Reproductive and sexual health
Measurements
AT
633.7 s
SonoVue plus oxytocin (group A)
Source sentences
Summary
In addition, EEF and AT were the shortest in group A (p < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
All participants underwent HIFU treatment safely, and the mean energy efficiency factor (EEF) in the four groups was 4.7 ± 0.9J/mm³, 8.5 ± 0.6J/mm³, 8.9 ± 0.7J/mm³, and 12.6 ± 1.8J/mm³, respectively, with the mean ablation time (AT) of 633.7 ± 55.1 s, 874.2 ± 65.6 s, 936.3 ± 85.2 s, and 1103.2 ± 96.2 s, respectively.
Summary · context
330 patients with adenomyosis were randomly assigned to SonoVue and oxytocin group (group A, n = 82), oxytocin (group B, n = 85), SonoVue (group C, n = 81), or the control (group D, n = 82) for HIFU ablation.
Summary · context
In group B, oxytocin was dripped 0.32 IU/min during ablation.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Show in the study text Report a problemFND-3476359405
06HumanNot a test of Oxytocin aloneRandomized controlled trialSafety outcome
In women with adenomyosis having HIFU ablation, adverse event rates did not differ significantly among the four groups, which included oxytocin alone and with SonoVue.
In plain wordsIn women with adenomyosis having ultrasound ablation, side effect rates did not differ significantly among the four treatment groups.
Peptide
Oxytocin
Outcome
No significant changeAdverse event incidence across the four groups
Study
n = 330
Outcome group
Adverse events · Whole body
Source sentences
Summary
The incidence rates of adverse events were not significantly different in the four groups (p > 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
330 patients with adenomyosis were randomly assigned to SonoVue and oxytocin group (group A, n = 82), oxytocin (group B, n = 85), SonoVue (group C, n = 81), or the control (group D, n = 82) for HIFU ablation.
Summary · context
In group B, oxytocin was dripped 0.32 IU/min during ablation.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Show in the study text Report a problemFND-3476359407
07HumanNot a test of Oxytocin aloneRandomized controlled trialEfficacy outcome
In women with adenomyosis having HIFU ablation, the combination of SonoVue and oxytocin gave a significantly higher non-perfused volume ratio than the control group.
In plain wordsIn women with adenomyosis having ultrasound ablation, SonoVue plus oxytocin gave a higher non-perfused volume ratio than no treatment add-on.
Peptide
Oxytocin
Outcome
IncreaseNon-perfused volume ratio with SonoVue plus oxytocin
Study
n = 164
Comparator
Control (neither oxytocin nor SonoVue)
Outcome group
Uterine fibroid outcomes · Reproductive and sexual health
Measurements
NPVR
90.4%
SonoVue plus oxytocin (group A)
NPVR
80.5%
control (group D)
Source sentences
Summary
NPVR was significantly higher in group A than in the control group D (p < 0.05).
3 context sentences(design, population, supporting numbers)
Summary · context
The non-perfused volume ratios (NPVR) were 90.4 ± 8.8%, 88.7 ± 9.1%, 89.4 ± 7.2%, 80.5 ± 7.9%, respectively.
Summary · context
330 patients with adenomyosis were randomly assigned to SonoVue and oxytocin group (group A, n = 82), oxytocin (group B, n = 85), SonoVue (group C, n = 81), or the control (group D, n = 82) for HIFU ablation.
Summary · context
In group B, oxytocin was dripped 0.32 IU/min during ablation.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Show in the study text Report a problemFND-3476359406

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 02:48 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.